We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
55 hedge funds and large institutions have $61.9M invested in Crescent Biopharma in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 19 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
106% more call options, than puts
Call options by funds: $247K | Put options by funds: $120K
33% more capital invested
Capital invested by funds: $46.6M → $61.9M (+$15.3M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 54 → 55 (+1)
0.02% less ownership
Funds ownership: 0.58% → 0.55% (-0.02%)
68% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 19
Holders
55
Holders Change
+1
Holders Change %
+1.85%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
6
Reduced
19
Closed
8
Calls
$247K
Puts
$120K
Net Calls
+$127K
Net Calls Change
+$13K
Top Buyers
| 1 |
BlackRock
New York
|
+$226K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$119K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$90.7K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$50.3K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$42.8K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$691K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$423K |
| 3 |
Two Sigma Investments
New York
|
-$303K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$245K |
| 5 |
Two Sigma Advisers
New York
|
-$240K |
